Breaking News, Collaborations & Alliances

Catalent Partners with Gene Editing Company Editas

Will provide services for the development and manufacturing of Editas’ cell and gene medicines.

By: Contract Pharma

Contract Pharma Staff

Genome editing company Editas Medicine, and Catalent, have entered into a partnership whereby Catalent will provide support for the development, manufacturing, and clinical supply of Editas Medicine’s current and future portfolio of in vivo CRISPR medicines and engineered cell medicines.   To date, Catalent has undertaken manufacturing and related services for Editas Medicine at its gene therapy manufacturing facility in Baltimore, MD. Through the extended partnership, Catalent will provide furt...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters